sever
acut
respiratori
syndrom
sar
main
proteas
proteas
essenti
propag
coronavir
life
cycl
regard
one
main
target
structurebas
antisar
drug
design
attract
approach
find
new
use
old
drug
alreadi
extens
clinic
test
could
easili
acceler
clinic
approv
briefli
perform
virtual
screen
databas
small
molecul
sar
analyz
inhibitorproteas
complex
identifi
sever
coval
noncoval
inhibitor
sever
old
drug
bind
sar
activ
site
select
silico
derivat
gener
coval
irrevers
inhibitor
enhanc
affin
furthermor
show
pharmacophor
deriv
cluster
compound
result
virtual
screen
could
use
probe
futur
structureact
relationship
studi
sar
finetun
lead
molecul
identifi
sever
acut
respiratori
syndrom
sar
lifethreaten
viral
respiratori
ill
caus
new
coronaviru
cov
viru
induc
symptom
atyp
pneumonia
clinic
indistinguish
similar
syndrom
thought
anim
origin
cours
month
sar
spread
rapidli
like
origin
guangdong
provinc
china
countri
world
health
organ
report
total
peopl
worldwid
becam
sick
sar
accompani
either
pneumonia
respiratori
distress
syndrom
patient
die
nation
laboratori
sever
biotechnolog
diagnost
firm
join
global
rush
combat
infecti
diseas
scientif
commun
alreadi
learnt
mani
import
lesson
hiv
could
acceler
antisar
drugvaccin
develop
declar
global
outbreak
sar
contain
new
case
report
august
howev
viru
yet
erad
import
protein
associ
sar
cov
infect
includ
polymeras
spike
glycoprotein
envelop
e
protein
membran
protein
nucleocapsid
n
protein
proteas
sar
play
pivot
role
viral
replic
one
potenti
target
structurebas
drug
design
sar
three
domain
residu
ii
iii
domain
ii
contain
activ
site
region
bbarrel
domain
iii
ahel
domain
sar
fold
similar
gener
serin
proteas
catalyt
cyshi
dyad
play
critic
role
activ
site
proteas
see
front
matter
elsevi
inc
right
reserv
reaction
conjur
activ
nucleophil
acidbas
catalyst
structur
conclus
activ
site
similar
within
coronaviru
famili
virtual
screen
homolog
model
provid
clue
regard
class
compound
could
interact
sar
proteas
rhinoviru
inhibitor
like
fit
activ
site
pocket
sar
deriv
could
potenti
inhibitor
sar
xray
crystal
structur
hrv
proteas
form
basi
earli
antisar
drug
design
pdb
support
observ
deriv
could
interact
activ
site
sar
proteas
six
hydrogen
bond
virtual
screen
model
sar
databas
proteas
inhibitor
show
avail
proteas
inhibitor
could
provid
clue
toward
antisar
drug
design
molecular
dynam
dock
studi
use
databas
fda
approv
compound
suggest
pseudo
symmetr
hiv
proteas
inhibitor
fit
well
activ
site
compar
toney
et
al
report
sanabandin
compound
nci
divers
set
could
inhibit
sar
proteas
first
crystal
structur
sar
report
juli
pdb
set
crystal
structur
includ
sar
complex
specif
hexapeptid
inhibitor
report
recent
pdb
bifunct
aryl
boron
acid
compound
target
cluster
serin
residu
near
activ
site
caviti
found
effect
proteas
inhibitor
junctur
research
revisit
old
adag
old
drug
new
bug
start
investig
old
drug
show
potenti
inhibit
replic
sarscov
shown
old
drug
could
use
templat
design
sar
inhibitor
sinc
old
drug
origin
design
inhibit
sar
finetun
interact
new
target
taught
kill
new
bug
present
studi
employ
silico
derivat
method
teach
old
drug
kill
new
bug
design
irrevers
coval
inhibitor
select
derivat
top
noncoval
lead
includ
sever
old
drug
especi
class
hiv
inhibitor
identifi
virtual
screen
studi
result
identif
sever
peptidomimet
small
molecul
candid
potenti
noncovalentcoval
inhibitor
sar
proteas
catalyt
activ
chain
sar
xray
crystal
structur
pdb
id
without
bound
cmk
peptid
water
molecul
use
studi
pdb
structur
result
structur
energi
minim
use
discov
modul
insight
ii
accelri
use
initi
structur
databas
compound
compris
proteas
inhibitor
aspartyl
cystein
serin
metalloproteas
hetatm
record
extract
pdb
http
wwwrcsborg
hiv
inhibitor
polymeras
integras
revers
transcriptas
set
thiol
reactiv
compound
filter
maybridg
http
wwwmaybridgecom
leadquest
http
wwwleadquestcom
acd
laboratori
http
wwwacdlabschemcom
nci
smallmolecul
databas
http
dtpncinihgov
use
studi
virtual
screen
small
molecul
inhibitor
sar
perform
use
flexx
modul
tripo
set
default
paramet
unless
otherwis
indic
text
util
multipl
wellknown
score
function
goldlik
function
docklik
function
chemscor
pmf
function
flexx
rank
order
complex
result
virtual
screen
list
top
compound
select
score
function
gener
purg
dataset
uniqu
compound
compound
subject
physicochem
filter
merg
singl
databas
compound
identifi
lead
molecul
silico
derivat
suitabl
thiol
reactiv
warhead
result
complex
subject
molecular
dynam
simul
energi
minim
use
discov
modul
insight
ii
molecular
dynam
simul
consist
initi
equilibr
pico
second
ps
follow
ps
dynam
k
final
complex
structur
end
md
simul
subject
step
steepest
descent
energi
minim
follow
conjug
gradient
energi
minim
calcul
distancedepend
dielectr
constant
nonbond
distanc
cutoff
use
molecular
graphic
imag
produc
use
ucsf
chimera
packag
comput
graphic
laboratori
univers
california
san
francisco
http
wwwcglucsfeduchimera
inhibitorproteas
interact
analyz
use
occlud
surfac
os
design
specif
inhibitor
block
sar
requir
clear
understand
success
inhibitor
design
class
cystein
proteas
first
set
specif
coval
inhibitor
proteas
design
ad
reactiv
warhead
diazo
compound
haloketon
good
substrat
proteas
concern
one
major
disadvantag
use
earli
coval
inhibitor
haloketon
aris
due
inher
reactiv
toward
nontarget
molecul
compromis
stabil
select
turn
make
unsuit
vivo
studi
discoveri
potent
natur
epoxysuccinyl
inhibitor
michael
acceptor
shown
lower
reactiv
warhead
essenti
increas
stabil
inhibitori
potenc
turn
make
viabl
vivo
studi
entri
clinic
trial
rejuven
interest
develop
irrevers
coval
inhibitor
cystein
proteas
essenti
first
step
subsit
map
librari
peptid
substrat
lieu
studi
often
easier
identifi
potenti
substrat
peptid
closer
homologu
within
famili
proteas
closer
examin
substrat
specif
profil
proteas
coronavirus
reveal
posit
substrat
usual
small
gli
ala
ser
conserv
gln
posit
posit
substrat
seem
favor
larg
hydrophob
residu
side
chain
mainchain
atom
form
subsit
confer
specif
toward
gln
thu
specif
coval
inhibitor
sar
could
design
substitut
amino
acid
posit
thiol
specif
reactiv
organ
moieti
like
chloromethyl
keton
affin
peptid
correct
pipi
etc
amino
acid
arrang
alway
highest
criteria
small
molecul
mimic
would
span
critic
length
requir
inhibit
make
critic
interact
bind
site
residu
secondari
structur
studi
use
peptid
substrat
demonstr
substrat
bsheet
like
structur
tend
react
fast
avail
xray
crystal
structur
bound
ligand
facilit
computerassist
design
structur
analogu
increas
potenc
due
lack
xray
crystal
structur
juli
construct
sever
homolog
model
base
tgev
mpro
pdb
id
though
signific
differ
homolog
model
avail
crystal
structur
comparison
rm
deviat
bind
site
structur
alon
respect
could
observ
differ
bind
site
local
loop
reorgan
side
chain
orient
fig
homolog
homologu
homolog
model
unb
model
model
ii
sar
crystal
structur
model
compar
model
avail
time
fig
mark
earli
structur
provid
structur
basi
initi
virtual
screen
effort
base
assumpt
substrat
peptid
bind
normal
mode
ie
conserv
sipi
si
pi
interact
etc
howev
report
cmkpeptid
bound
crystal
structur
partial
solvent
access
interact
subsit
result
shift
subsit
interact
occupi
subsit
respect
unusu
mode
bind
could
attribut
lower
specif
acid
comparison
coronavirus
author
also
report
larg
cooper
movement
side
chain
n
terminu
partner
protom
dimer
function
ph
especi
mark
differ
amongst
structur
crystal
differ
ph
pdb
fig
mark
ii
earlier
virtual
screen
studi
homolog
model
sar
provid
clue
potenti
proteas
inhibitor
elimin
molecul
poor
score
base
earli
virtual
screen
studi
sar
homolog
model
reduc
unwant
molecul
also
reduc
comput
time
taken
virtual
screen
xray
crystal
structur
outlin
materi
method
virtual
screen
result
uniqu
compound
small
molecul
hit
contain
least
one
thiol
reactiv
function
group
compound
could
potenti
serv
coval
inhibitor
sar
analysi
dock
complex
reveal
thiol
reactiv
function
group
properli
orient
toward
catalyt
dock
complex
complex
compound
includ
orient
properli
toward
still
away
induc
possibl
nucleophil
attack
reorgan
ligand
fragment
provid
proper
orient
proteas
reaction
disrupt
critic
interact
bind
site
residu
process
learnt
easier
modifi
small
molecul
contain
thiol
function
bind
well
proteas
pocket
apart
potenti
coval
inhibitor
virtual
screen
also
result
molecul
contain
thiol
reactiv
function
base
visual
examin
select
small
molecul
bind
substratebind
pocket
mimick
sever
critic
hydrogen
bond
interact
similar
cmk
peptid
identifi
noncoval
inhibitor
compos
sever
popular
hiv
proteas
inhibitor
shown
fig
pharmacophor
deriv
cluster
compound
result
virtual
screen
form
excel
data
set
futur
structureact
relationship
studi
sar
observ
hiv
proteas
inhibitor
share
similar
pharmocophor
featur
fig
structur
structurebas
search
pharmacophor
use
crossfir
command
mdl
result
molecul
variou
function
group
posit
fig
show
dock
pose
success
hit
identifi
compound
sar
site
steric
substitu
highlight
red
fig
alter
score
drastic
compar
function
group
posit
molecul
hydroxylor
aminogroup
posit
favor
molecul
could
potenti
serv
directli
noncoval
inhibitor
sar
provid
templat
design
coval
inhibitor
describ
follow
section
reexamin
set
noncoval
inhibitor
bound
complex
observ
class
hiv
inhibitor
fit
well
sar
activ
site
attempt
design
irrevers
coval
inhibitor
top
candid
virtual
screen
subject
rulebas
secondari
screen
select
small
molecul
lie
within
away
sc
result
candid
subject
silico
derivat
thiol
reactiv
organ
warhead
incorpor
appropri
chemic
viabl
posit
shown
fig
warhead
coval
ligat
sc
structur
reminim
bump
structur
deform
aris
new
linkag
care
elimin
visual
examin
studi
incorpor
thiolreact
organ
moieti
warhead
extract
coval
inhibitor
identifi
studi
fast
slow
reactiv
shown
fig
analys
inhibitorbound
complex
reveal
coval
inhibitor
pick
interact
compar
noncoval
analogu
list
top
noncoval
inhibitor
select
secondari
rulebas
screen
function
group
select
silico
derivat
highlight
red
fig
graphic
illustr
cyclic
ureabas
noncoval
inhibitor
color
orang
coval
analogu
color
cornflow
blue
bound
sar
activ
site
shown
fig
visual
examin
interact
residu
show
coval
inhibitor
interact
bind
site
residu
much
better
noncoval
analogu
cmk
peptid
inhibitor
form
six
hydrogen
bond
activ
site
residu
pdb
top
rank
inhibitor
pick
studi
form
least
hydrogen
bond
correspond
interact
residu
follow
fig
illustr
dock
pose
cmk
peptid
hiv
inhibitor
noncoval
inhibitor
coval
irrevers
analogu
hiv
inhibitor
respect
sar
pocket
occlud
surfac
program
os
packag
program
calcul
occlud
surfac
atom
pack
protein
structur
develop
pattabiraman
et
al
use
analyz
inhibitorproteas
interact
occlud
surfac
defin
molecular
surfac
less
surfac
neighbor
nonbond
atom
water
molecul
fit
two
atom
occlud
occlud
surfac
similar
buri
surfac
sensit
pack
geometri
buri
surfac
use
roll
probe
calcul
occlud
surfac
normal
molecular
surfac
extend
outward
intersect
neighbor
van
der
waal
surfac
collect
extend
normal
respect
length
defin
pack
atom
structur
model
combin
occlud
surfac
area
averag
length
normal
use
obtain
occlud
surfac
pack
osp
valu
residu
analysi
interchain
occlud
surfac
allow
detail
calcul
proteinprotein
interact
surfac
osidentifi
interact
residu
sar
activ
site
highlight
fig
occlud
surfac
score
ligand
atom
correspond
atom
bind
site
gener
os
score
averag
per
amino
acid
give
quantit
measur
proteininhibitor
interact
noncoval
inhibitor
interact
catalyt
residu
correspond
coval
analogu
interact
better
cmk
peptid
fig
cmk
peptid
coval
inhibitor
bound
higher
os
score
residu
compar
correspond
noncoval
analogu
fig
howev
noncoval
inhibitor
interact
residu
better
coval
cmk
peptid
evid
os
score
could
quantit
differenti
interact
coval
noncoval
analogu
hiv
inhibitor
bind
site
residu
sar
process
vitro
biolog
test
top
noncoval
inhibitor
use
clone
sar
proteas
initi
ex
silico
derivat
top
coval
irrevers
inhibitor
identifi
studi
result
would
help
focu
substrateoptim
lead
discoveri
use
structurebas
screen
identifi
compound
bind
sar
site
molecul
could
potenti
retard
proteolyt
action
sar
proteas
use
combin
antivir
therapeut
proteas
inhibitor
design
evolv
beyond
mere
addit
reactiv
warhead
cognat
proteas
substrat
silico
derivat
viabl
function
group
identifi
secondari
rulebas
screen
enabl
old
drug
react
serv
center
nucleophil
attack
use
low
high
reactiv
organ
warhead
provid
mean
control
reactiv
inhibitor
stabil
inhibitori
potenc
turn
help
design
inhibitor
viabl
vivo
studi
thu
strategi
educ
old
drug
kill
new
bug
also
teach
behav
accord
need
occlud
surfac
gener
score
provid
uniqu
novel
method
quantit
comparison
noncoval
coval
inhibitor
bound
complex
unlik
new
drug
old
drug
drug
minim
modif
undergo
extens
preclin
test
prove
safeti
efficaci
possibl
gain
acceler
approv
us
food
drug
administr
strategi
could
extend
identifi
potent
inhibitor
finetun
old
drug
diseas
target
cystein
proteas
cathepsin
caspas
calpain
papain
